Related Experiment Video
Updated: May 10, 2025
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Identification and exploration of key genes associated with radioresistance in lung adenocarcinoma
Ying Wang1, Yangyang Shang2,3, Mingyu Hua1
1Department of Radiation Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Background:
Radiation resistance in lung adenocarcinoma (LUAD) remains a primary obstacle limiting radiotherapy efficacy. However, the detailed factors and molecular mechanisms influencing LUAD radiosensitivity are not fully understood.
Methods:
Radioresistance-related genes (RRRGs) were screened by RNA sequencing and bioinformatics analysis, and a prediction model for radiotherapy efficacy was developed via LASSO-Cox regression analysis. We specifically focused on Stanniocalcin 2 (STC2) due to its prognostic significance and validated its expression through immunohistochemical staining (IHC) in pathological samples from LUAD patients. A STC2 knockdown (siSTC2) A549 cell line was created, and Western blotting, CCK8, and colony formation assays were performed to investigate STC2's involvement in radioresistance.
Results:
An efficacy prediction model was constructed using 6 RRRGs (FCGBP, SLCO4A1, ALDH3A1, STC2, TERT, CYP24A1). IHC analysis of 74 LUAD patients showed significantly higher STC2 expression in radiotherapy non-responders (N-Res) versus responders (Res) (p < 0.05). Patients with elevated STC2 levels experienced shorter overall survival (OS). Western blotting revealed higher STC2 expression in irradiated (IR) A549 cells compared to non-irradiated (N-IR) (p < 0.05). CCK8 assays results suggested that knockdown of STC2 resulted in a significant reduction in cell proliferation ability (p < 0.05), and colony formation assays confirmed a significant decrease in clonogenic ability of siSTC2 cells compared to controls (p < 0.05).
Conclusion:
STC2 plays a significant role in mediating LUAD cell radioresistance, with high expression correlating with poor prognosis. Therefore, STC2 represents a promising therapeutic target for overcoming LUAD radioresistance.
Clinical Trial Number:
Not applicable.
Insights
High Stanniocalcin 2 (STC2) expression in lung adenocarcinoma (LUAD) correlates with resistance to radiation therapy and poor patient survival. Targeting STC2 may improve radiotherapy outcomes for LUAD patients.
Area of Science:
- Oncology
- Molecular Biology
- Radiotherapy Research
Background:
- Radiation resistance is a major challenge in treating lung adenocarcinoma (LUAD).
- The molecular mechanisms underlying LUAD radiosensitivity are not fully understood.
Purpose of the Study:
- To identify radioresistance-related genes (RRRGs) in LUAD.
- To develop a prediction model for radiotherapy efficacy.
- To investigate the role of Stanniocalcin 2 (STC2) in LUAD radioresistance.
Main Methods:
- RNA sequencing and bioinformatics analysis to screen RRRGs.
- LASSO-Cox regression for model development.
- Immunohistochemical staining (IHC) to validate STC2 expression in LUAD patient samples.
- Cell line experiments (siSTC2) with Western blotting, CCK8, and colony formation assays.
Main Results:
- A 6-gene prediction model for radiotherapy efficacy was established, including STC2.
- Elevated STC2 expression was observed in non-responders to radiotherapy and correlated with shorter overall survival in LUAD patients.
- STC2 knockdown significantly reduced proliferation and clonogenic ability in LUAD cells.
Conclusions:
- STC2 is a significant mediator of radioresistance in LUAD.
- High STC2 expression is associated with poor prognosis in LUAD patients.
- STC2 represents a potential therapeutic target to enhance radiotherapy efficacy in LUAD.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...